DASATINIB IN CHRONIC MYELOID LEUKEMIA
BACKGROUND The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosomepositive CML (chronic myeloid leukemia), but relaps occurs, mainly as a reults of the outgrowth of leukemic subclones with imatinib resistant BCR-ABL mutation.Some patientswith various phases of CML note...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Slovenian Medical Association
2008-04-01
|
| Series: | Zdravniški Vestnik |
| Online Access: | http://vestnik.szd.si/index.php/ZdravVest/article/view/908 |